The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

9:00 a.m.-12:00 p.m. CDT Session Type and Title: Poster Session – Head and Neck Cancer Poster Board Number: 445 Presenter: Jared Weiss, M.D., Section Chief of Thoracic and Head/Neck Oncology ...

There are over 100 types of human papillomavirus (HPV), and some can lead to different types of cancer, including cancer that affects the nose and throat. These are known as HPV-associated ...

Doctors are saying human papillomavirus (HPV) infections, a sexually transmitted disease, are causing the spike in cases. Head and neck cancers have traditionally been associated with smoking and ...

Pap tests and HPV testing are a vital part of women's health care, but many people dread the invasive examination every three years. For some women, particularly sexual violence survivors ...

The reported noted that the decrease is alarming as HPV vaccination rates have remained “statistically unchanged” in recent years. In 2023, 61.4% of adolescents ages 13 to 17 were up-to-date ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

The abstracts will be available on the ASCO® website on May 22, 2025 at 5:00 p.m. ET. The full presentation will be available on the Merus website at the start of the session.

Routman, during a dedicated poster session. PDS Biotech is committed to innovating immunotherapy approaches for cancer treatment, specifically targeting HPV-associated cancers. PDS Biotech will ...